| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KLb |
| Uniprot No | Q86Z14 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1044aa |
| 氨基酸序列 | MKPGCAAGSPGNEWIFFSTDEITTRYRNTMSNGGLQRSVILSALILLRAVTGFSGDGRAIWSKNPNFTPVNESQLFLYDTFPKNFFWGIGTGALQVEGSWKKDGKGPSIWDHFIHTHLKNVSSTNGSSDSYIFLEKDLSALDFIGVSFYQFSISWPRLFPDGIVTVANAKGLQYYSTLLDALVLRNIEPIVTLYHWDLPLALQEKYGGWKNDTIIDIFNDYATYCFQMFGDRVKYWITIHNPYLVAWHGYGTGMHAPGEKGNLAAVYTVGHNLIKAHSKVWHNYNTHFRPHQKGWLSITLGSHWIEPNRSENTMDIFKCQQSMVSVLGWFANPIHGDGDYPEGMRKKLFSVLPIFSEAEKHEMRGTADFFAFSFGPNNFKPLNTMAKMGQNVSLNLREALNWIKLEYNNPRILIAENGWFTDSRVKTEDTTAIYMMKNFLSQVLQAIRLDEIRVFGYTAWSLLDGFEWQDAYTIRRGLFYVDFNSKQKERKPKSSAHYYKQIIRENGFSLKESTPDVQGQFPCDFSWGVTESVLKPESVASSPQFSDPHLYVWNATGNRLLHRVEGVRLKTRPAQCTDFVNIKKQLEMLARMKVTHYRFALDWASVLPTGNLSAVNRQALRYYRCVVSEGLKLGISAMVTLYYPTHAHLGLPEPLLHADGWLNPSTAEAFQAYAGLCFQELGDLVKLWITINEPNRLSDIYNRSGNDTYGAAHNLLVAHALAWRLYDRQFRPSQRGAVSLSLHADWAEPANPYADSHWRAAERFLQFEIAWFAEPLFKTGDYPAAMREYIASKHRRGLSSSALPRLTEAERRLLKGTVDFCALNHFTTRFVMHEQLAGSRYDSDRDIQFLQDITRLSSPTRLAVIPWGVRKLLRWVRRNYGDMDIYITASGIDDQALEDDRLRKYYLGKYLQEVLKAYLIDKVRIKGYYAFKLAEEKSKPRFGFFTSDFKAKSSIQFYNKVISSRGFPFENSSSRCSQTQENTECTVCLFLVQKKPLIFLGCCFFSTLVLLLSIAIFQRQKRRKFWKAKNLQHIPLKKGKRVVS |
| 预测分子量 | 119,8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KLb重组蛋白的假设性参考文献示例(仅供参考，实际文献需通过学术数据库查询)：
---
1. **文献名称**：*Structural and Functional Analysis of Recombinant KLb Protein in FGF21 Signaling*
**作者**：Chen, L., et al.
**摘要**：本研究成功在大肠杆菌中表达并纯化重组KLb蛋白，通过体外实验证实其与FGF21及FGFR1c形成三元复合物，揭示了KLb在调节糖代谢中的分子机制。
2. **文献名称**：*KLb Recombinant Protein Ameliorates Hepatic Steatosis in Obese Mouse Models*
**作者**：Kim, S., et al.
**摘要**：利用哺乳动物细胞系统表达的重组KLb蛋白，在肥胖小鼠模型中验证了其通过增强FGF21信号通路改善脂肪肝和胰岛素敏感性的效果。
3. **文献名称**：*Development of a High-Yield KLb-Fc Fusion Protein for Therapeutic Applications*
**作者**：Zhang, Y., et al.
**摘要**：报道了一种KLb-Fc融合蛋白的稳定表达策略，通过延长半衰期和增强生物活性，为代谢综合征的蛋白质药物开发提供了新思路。
4. **文献名称**：*KLb Knockout and Rescue Models Highlight Its Role in Bile Acid Metabolism*
**作者**：Garcia, A., et al.
**摘要**：利用重组KLb蛋白回补实验，证明KLb缺失会导致胆汁酸代谢紊乱，补充重组蛋白可恢复相关基因表达，提示其潜在临床应用价值。
---
如需真实文献，建议在 **PubMed** 或 **Web of Science** 中搜索关键词：
`KLB protein recombinant`, `FGF21 KLB signaling`, `Klotho beta recombinant expression`。
KLb, also known as β-Klotho, is a transmembrane protein belonging to the Klotho family, which includes α-Klotho and β-Klotho. Discovered in the early 2000s, KLb gained attention for its role as a co-receptor in fibroblast growth factor (FGF) signaling pathways, particularly mediating the metabolic effects of FGF19 and FGF21. Unlike α-Klotho, which is primarily linked to phosphate and vitamin D regulation, KLb is highly expressed in metabolic tissues such as the liver, adipose tissue, and pancreas, where it partners with FGF receptors (FGFRs) to enable ligand-specific signaling.
Structurally, KLb features a large extracellular domain with two glycosidase-like regions, a single transmembrane segment, and a short intracellular tail. Its interaction with FGFR1c or FGFR4 is critical for FGF19/FGF21 binding and downstream activation of pathways regulating glucose homeostasis, lipid metabolism, and energy expenditure. Notably, the KLb-FGF21 axis has emerged as a key target for treating metabolic disorders like obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH), due to its insulin-sensitizing and weight-reducing effects.
Recombinant KLb proteins are engineered for research and therapeutic development, often used to study receptor-ligand interactions or screen FGF21 analogs. Challenges remain in optimizing KLb-based therapies, including tissue-specific targeting and minimizing off-effects. Recent advances in structural biology and antibody engineering have improved understanding of KLb’s mechanistic roles, spurring clinical trials for KLb-targeting agents. Its dual function as a metabolic regulator and disease modifier continues to drive interest in precision medicine approaches for metabolic syndromes.
×
